Fulgent Genetics Inc logo

Fulgent Genetics Inc(FLGT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$24.66
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FLGT

11/13/2026: FLGT (1-star) is currently NOT-A-BUY. Pass it for now.

Fulgent Genetics Inc is a healthcare diagnostics company specializing in genetic testing, next-generation sequencing, and anatomic pathology services. The company's primary strengths include a robust net cash balance sheet and a scalable technology infrastructure that supports custom diagnostic panels. Its primary growth opportunity lies in expanding precision oncology offerings and specialized laboratory services, though it faces persistent operating losses and intense competition from larger reference labs. The stock suits growth-oriented or opportunistic investors comfortable with volatility and regulatory uncertainties surrounding laboratory-developed tests. Key developments to monitor include core testing volume trends, cost management initiatives, and progress in the therapeutic pipeline.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitCore genetic testing markets offer long-term expansion, but current top-line growth is recovering from pandemic-era highs.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp trading swings around earnings updates and diagnostic volume news.
Value investorMixed fitTrading below net cash per share provides asset backing, though persistent operating losses temper pure value appeal.
Dividend investorWeak fitThe company does not pay a dividend, focusing its capital allocation elsewhere.
Low-risk investorWeak fitUnprofitable operations and regulatory uncertainties surrounding diagnostic billing create structural risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highEquities in diagnostic biotech frequently fluctuate based on reimbursement updates and quarterly volume reports.
Valuation riskMediumWhile buffered by net cash, market valuations are sensitive to shifts in operating cash burn.
Competition risk (molecular diagnostics and reference labs)HighIntense competition from massive reference laboratories limits pricing power.
Business qualityMediumProprietary technology platforms provide strong technical capabilities, though profitability remains challenged.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskMedium / highSuccessfully scaling oncology diagnostics and therapeutic programs requires flawless clinical execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 688.98M USD
Price to earnings Ratio -
1Y Target Price 25
Price to earnings Ratio -
1Y Target Price 25
Volume (30-day avg) 352.4K shares
Beta 1.02
52 Weeks Range 13.46 - 31.04
Updated Date 11/15/2026
52 Weeks Range 13.46 - 31.04
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.1

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -2.33%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
FLGT receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
FLGT has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+13.8%) is partially offset by negative earnings growth (-41.7%), weak cash generation (FCF margin -38.5%), weak profitability (net margin -18.8%).

Financial Health Rating

★★★★★
FLGT's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 38.4%). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is FLGT's strongest growth driver at +13.8% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-41.7%, negative) and free-cash-flow growth (-545.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 55.8% and approximately 61.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 37.24% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.24%
Acadian Asset Management LLC 3.93%
Vanguard Capital Management, LLC 2.84%
Jacobs Levy Equity Management, Inc. 2.82%
JPMorgan Chase & Co 2.73%

Unit Economics (Per $1K Revenue)

★★★★★
FLGT generates approximately $406 of gross profit, $-282 of operating income, and $-385 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 11.99%

Quantitative Style Profile

★★★★★
FLGT has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Laboratory ServicesClinical diagnostic testing, molecular sequencing, hereditary panels, and anatomic pathology services billed to hospitals, payors, and patients.This is the primary revenue driver where customers pay for specialized medical diagnostic tests.
Therapeutic DevelopmentPreclinical and clinical drug candidates focused on oncology applications utilizing proprietary delivery mechanisms.An exploratory long-term segment aimed at drug development rather than immediate commercial lab billing.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 7.7
Enterprise Value 407.35M
Price to Sales(TTM) 2.09
Enterprise Value 407.35M
Price to Sales(TTM) 2.09
Enterprise Value to Revenue 1.23
Enterprise Value to EBITDA 2.34
Shares Outstanding 27.94M
Shares Floating 17.12M
Shares Outstanding 27.94M
Shares Floating 17.12M
Percent Insiders 37.24
Percent Institutions 55.84

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.